Loading...
 
Mediterr J Rheumatol 2021;32(4):376-7
Eosinophilic Fasciitis following Checkpoint Inhibitor Therapy with Pembrolizumab
Authors Information

1. Rheumatology Department, Lefkos Stavros - The Athens Clinic, Athens, Greece

2. 7th Pulmonary Department and Central Bronchoscopic Unit “Christos Gagas” NHS, Athens Chest Hospital "Sotiria", Athens, Greece

E. Zampeli, E. Zervas

References
  1. Zampeli E, Moutsopoulos HM. In: Immunology and Rheumatology in Questions, Zampeli E, Moutsopoulos HM, Editors. Springer Nature Switzerland AG. 2021. P.128-129.
  2. Zampeli E, Pantelidaki A, Moutsopoulos HM. Evolution of one systemic rheumatic disease into another: scleroderma evolving to eosinophilic fasciitis with myositis. Clin Exp Rheumatol 2019;4:149-50.
  3. Jinnin M, Yamamoto T, Asano Y, Ishikawa O, Sato S, Takehara K, et al. Diagnostic criteria, severity classification and guidelines of eosinophilic fasciitis. J Dermatol 2018;45:881-90.
  4. Lebeaux D, Sène D. Eosinophilic fasciitis (Shulman disease) Best Pract Res Clin Rheumatol 2012;26:449-58. 
  5. Moulton SJ, Kransdorf MJ, Ginsburg WW, Abril A, Persellin S. Eosinophilic fasciitis: spectrum of MRI findings. AJR Am J Roentgenol 2005;184:975-8. 
  6. Chan KK, Magro C, Shoushtari A, Rudin C, Rotemberg V, Rossi A, et al. Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature. Oncologist 2020;25:140-9.